Intra-Cellular Therapies Inc.

NASDAQ: ITCI
Share price (1/8/25): $82.56
Market cap (1/8/25): $8.753 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Automatic shelf registration

Prospectus supplement for primary offering

Ownership Filter

Halstead Michael

News Filter

Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients With Schizophrenia

Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Change in Directors, Officers or Compensation, Shareholder Vote Results, Financial Statements or Exhibits

Proxies Filter

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission

Scanned paper annual report submission